Side-by-side · Research reference
MOTS-cvsPEG-MGF
Side-by-side comparison across mechanism, dosage, evidence, side effects, administration, and stack synergies. Citations on every claim where available.
AAnimal-StrongHUMAN-REVIEWED16/68 cited
BAnimal-MechanisticHUMAN-REVIEWED2/69 cited
MOTS-c
Mitokine · Mitochondria-Encoded
SQ · Variable · 2–3×/week
PEG-MGF
IGF-1Ec Splice Variant · PEGylated
~2 hrHalf-life (PEG)
~7 minNative MGF t½
IGF-1EcSplice variant
SQ · Research Protocol
01Mechanism of Action
Parameter
MOTS-c
PEG-MGF
Primary target
Mitochondrial 12S rRNA sORF → folate-AICAR-AMPK axisLee 2015
IGF-1 receptor on muscle satellite cells and myocytes
Pathway
IGF-1R → PI3K/Akt → mTOR activation → Satellite cell proliferation & myoblast fusion
Downstream effect
Enhanced fatty acid oxidation, GLUT4-mediated glucose uptake, mitochondrial bioenergetics, anti-inflammationLee 2015
Satellite cell activation, muscle fiber repair, localized hypertrophy signaling
Feedback intact?
Stress-responsive, AMPK-dependent nuclear translocationKim 2018
Partially bypassed — does not require hepatic IGF-1 synthesis
Origin
Endogenous 16-AA mitokine; mtDNA-encoded; declines with age; upregulated by exerciseReynolds 2021
IGF-1Ec splice variant (exon 4–6) conjugated to polyethylene glycol for extended circulation
Antibody development
—
Unknown — no long-term human immunogenicity data
02Dosage Protocols
Parameter
MOTS-c
PEG-MGF
Standard dose
5–10 mg / weekLee 2015
Experimental, extrapolated from animal data. No human RCT-derived dose.
—
Frequency
2–3× per week
Short half-life may necessitate more frequent dosing for saturation.
Post-training or daily
Timing to match endogenous MGF pulse post-exercise.
Lower / starter dose
2.5–5 mg / week
Recommended due to limited human data.
—
Evidence basis
Animal + anecdotalLee 2015Reynolds 2021A first-in-human phase 1 study 2021
Phase 1a/1b CB4211 analog trial completed 2021; no native MOTS-c RCT published.
Animal / mechanistic
Duration
4–12 weeks (experimental)
Optimal cycle length unknown.
—
Reconstitution
Bacteriostatic water, 1–2 mL
10 mg/mL at 1 mL.
Sterile bacteriostatic water
Lyophilized form; store reconstituted at 2–8 °C.
Timing
Pre-workout or fasted state preferred
Activity-context amplifies AMPK response.
Within 30–60 min post-training
Aligns with endogenous MGF window.
Half-life
Minutes to hours (estimated)
Systemically unstable; native MOTS-c PK in humans not fully characterised.
~2 hours (PEGylated)
Native MGF: ~7 min; PEGylation extends circulation.
Research dose range
—
100–200 mcg
Extrapolated from animal models; no validated human protocols.
PEG molecular weight
—
Typically 5–30 kDa
Higher MW = longer t½, greater steric hindrance.
03Metabolic / Fat Loss Evidence
Parameter
MOTS-c
PEG-MGF
Primary fat target
Diet-induced / metabolic obesity; systemic fat utilization
—
Quantified reduction
Significant HFD fat gain ↓Lee 2015
Murine models, dose-dependent (5 & 15 mg/kg).
—
IGF-1 impact
No direct IGF-1 pathway; AMPK-mediated
—
Effect on lean mass
High dose significantly ↑ lean mass in mice
—
Triglycerides
AMPK-driven FA oxidation suggests TG benefit (not directly measured)
—
Effect reversibility
Unknown — no long-term follow-up data
—
Key publication
Lee Cell Metab 2015 · Reynolds Nat Commun 2021 · Kim Cell Metab 2018Lee 2015Reynolds 2021Kim 2018
—
Primary target
—
Muscle tissue (satellite cells, myocytes) — not adipose-specific
Indirect metabolic effect
—
IGF-1 signaling may modulate insulin sensitivity and lipid metabolismRen 2015
Mechanism distinct from direct lipolytic peptides.
Body composition
—
Lean mass preservation / hypertrophy focus
Fat loss evidence
—
No direct human or animal RCT data for PEG-MGF-driven fat reduction
04Side Effects & Safety
Parameter
MOTS-c
PEG-MGF
Injection site reaction
Mild irritation (reported)
Erythema, induration (common with SQ peptides)
Fluid retention / Edema
Not reported
—
Cardiovascular
Heart palpitations (anecdotal); cardiac hypertrophy reversed in diabetic rats
—
Cancer risk
Contradictory data — some models suggest pro-proliferative effects
IGF-1 axis stimulation contraindicated in active malignancy
CNS / Neurological
Insomnia, headache (anecdotal reports)
—
GI symptoms
Nausea, stomach discomfort (reported)
—
Antibody formation
No data (no long-term human trials)
PEGylated proteins can elicit anti-PEG antibodies (neutralizing potential unknown)
Pregnancy / OB
Avoid — insufficient safety data
—
Evidence quality
Phase 1 analog (CB4211); preclinical; anecdotal humanA first-in-human phase 1 study 2021
—
Hypoglycemia risk
—
IGF-1 axis activation can lower blood glucose
IGF-1R overstimulation
—
Theoretical risk of aberrant cell proliferation with chronic supraphysiological exposure
Fluid retention
—
Possible with IGF-1 pathway activation (dose-dependent)
PEG accumulation
—
Chronic high-dose PEGylated proteins may accumulate in tissues; clearance slower in renal impairment
Human safety data
—
Absent — no published human trials for PEG-MGF
Absolute Contraindications
MOTS-c
- ·Pregnancy / breastfeeding (insufficient data)
PEG-MGF
- ·Active malignancy or history of cancer (IGF-1R proliferative signaling)
- ·Known hypersensitivity to PEGylated compounds
- ·Pregnancy / lactation (no reproductive toxicity data)
Relative Contraindications
MOTS-c
- ·Active cancer or cancer predisposition
- ·AMPK pathway deficiency (efficacy nullified)
- ·Use with cancer-promoting medications (theoretical)
PEG-MGF
- ·Diabetes (monitor glucose closely)
- ·Renal impairment (PEG clearance reduced)
- ·Retinopathy (IGF-1 axis effects on vascular proliferation)
05Administration Protocol
Parameter
MOTS-c
PEG-MGF
1. Reconstitution
Add 1–2 mL bacteriostatic water. At 10 mg/vial, 1 mL gives 10 mg/mL concentration. Roll gently to dissolve.
Add 1–2 mL bacteriostatic water to lyophilized vial. Swirl gently — do not shake. Solution should be clear to slightly opalescent.
2. Injection site
Subcutaneous — abdomen, thigh, or deltoid. Rotate sites to avoid lipohypertrophy. Pinch fat layer.
Subcutaneous — abdomen or thigh. Rotate sites to avoid lipodystrophy. Avoid areas with scar tissue or active inflammation.
3. Timing
Pre-workout or fasted state preferred — metabolic context amplifies AMPK response. 2–3× per week.
Post-training preferred (within 30–60 min) to align with endogenous MGF expression window. Alternatively, daily morning dose on non-training days.
4. Storage
Lyophilised: room temp, protected from light. Reconstituted: refrigerate, use within 21–30 days. Short systemic stability.
Lyophilized: room temperature, light-protected, desiccated. Reconstituted: refrigerate 2–8 °C, use within 14–21 days.
5. Needle
27–31G insulin syringe. Short needle (4–6 mm) for SQ delivery. Clean technique mandatory.
29–31G insulin syringe, 8–12 mm length. Pinch skin fold, insert at 45° angle for subcutaneous delivery.
06Stack Synergy
MOTS-c
+ Ipamorelin
ModerateMOTS-c activates AMPK/PGC-1α for mitochondrial efficiency and fatty acid oxidation; ipamorelin stimulates GH for anabolic recovery and sleep depth. Pathways are complementary — MOTS-c handles metabolic flexibility and glucose handling while ipamorelin drives recovery and body recomposition through GH. Theoretical synergy is high; clinical data is lacking.
- MOTS-c
- 5 mg SQ · pre-workout (2–3×/wk)
- Ipamorelin
- 200–300 mcg SQ · pre-sleep (daily)
- Primary benefit
- Metabolic flexibility + GH recovery + ROS reduction
PEG-MGF
+ BPC-157
ModerateBPC-157 promotes angiogenesis and tendon/ligament repair via VEGF and growth factor modulation, while PEG-MGF targets satellite cell activation and myocyte proliferation. Complementary pathways for comprehensive tissue repair post-injury or intensive training. BPC-157's systemic stability and oral bioavailability contrast with PEG-MGF's localized IGF-1R signaling.
- PEG-MGF
- 100–200 mcg SQ post-training
- BPC-157
- 250–500 mcg SQ or oral, twice daily
- Duration
- 4–6 weeks (injury-dependent)
- Primary benefit
- Accelerated muscle and connective tissue repair, enhanced recovery
+ TB-500
StrongTB-500 (Thymosin Beta-4 fragment) upregulates actin polymerization, cell migration, and anti-inflammatory pathways, while PEG-MGF drives satellite cell proliferation via IGF-1R/mTOR. Synergistic for muscle regeneration: TB-500 mobilizes progenitor cells, PEG-MGF stimulates their differentiation into myocytes. Both have overlapping but distinct repair cascades.
- PEG-MGF
- 100–200 mcg SQ post-training
- TB-500
- 2–5 mg SQ, 2× per week (loading), then weekly
- Timing
- Stagger injections by 6–12 hours
- Primary benefit
- Maximal satellite cell recruitment and myogenic differentiation, injury repair